Semaglutide
Semaglutide is a pharmaceutical drug with 313 clinical trials. Currently 72 active trials ongoing. Historical success rate of 98.9%.
Success Metrics
Based on 187 completed trials
Phase Distribution
Phase Distribution
70
Early Stage
60
Mid Stage
130
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
95.4%
187 of 196 finished
4.6%
9 ended early
72
trials recruiting
313
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes
Semaglutide Therapy for Alcohol Reduction (STAR)
Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM
Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight
Clinical Trials (313)
A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes
Semaglutide Therapy for Alcohol Reduction (STAR)
Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM
Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
Semaglutide (Wegovy) Treatment for Trichotillomania
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
Focusing on the Menopausal Transition to Improve Mid-Life Women's Health
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1
A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight
A Non-interventional Study Investigating Semaglutide in Combination With Lifestyle-based Modifications for the Management of Obesity in Real-World Clinical Practice in Germany (WeGo Real Germany).
A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight
Simultaneous Starting of the 4 Guideline Directed CKD Therapies (RAPID-CKD)
A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)
Special Use - Results Surveillance on Long-term Use With Wegovy®
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 313